Abstract
The majority of humans have been infected with Herpes Simplex Virus Type 1 (HSV-1) and harbor its viral DNA in the latent form within neurons for lifetime. This, combined with the absence of serious adverse effects due to HSV-1 derived vectors in clinical trials so far, highlight the potential to use this virus to develop neuronal gene transfer vectors which are transparent to the host, allowing the effects of the transgene to act without interference from the transfer system eg., for functional genomics in basic neuroscience or gene therapy of neurological disorders. On the other hand, other HSV-1 derived vectors which also have a promising perspective in the clinic, are designed to have enhanced cytotoxicity in certain cell types, as in the case of oncolytic vectors. Understanding virus-host interactions is fundamental not only to the success of these gene therapy vectors but also with respect to identifying and minimizing biohazards associated with their use. In this review we discuss characteristics of HSV-1 and gene therapy vectors derived from this virus which are useful to consider in the context of biosafety risk assessment and risk management.
Keywords: Herpesvirus, HSV-1, biosafety, viral vector, gene transfer, neurological gene therapy.
Current Gene Therapy
Title:Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1
Volume: 13 Issue: 6
Author(s): Filip Lim, Hena Khalique, Maria Ventosa and Aline Baldo
Affiliation:
Keywords: Herpesvirus, HSV-1, biosafety, viral vector, gene transfer, neurological gene therapy.
Abstract: The majority of humans have been infected with Herpes Simplex Virus Type 1 (HSV-1) and harbor its viral DNA in the latent form within neurons for lifetime. This, combined with the absence of serious adverse effects due to HSV-1 derived vectors in clinical trials so far, highlight the potential to use this virus to develop neuronal gene transfer vectors which are transparent to the host, allowing the effects of the transgene to act without interference from the transfer system eg., for functional genomics in basic neuroscience or gene therapy of neurological disorders. On the other hand, other HSV-1 derived vectors which also have a promising perspective in the clinic, are designed to have enhanced cytotoxicity in certain cell types, as in the case of oncolytic vectors. Understanding virus-host interactions is fundamental not only to the success of these gene therapy vectors but also with respect to identifying and minimizing biohazards associated with their use. In this review we discuss characteristics of HSV-1 and gene therapy vectors derived from this virus which are useful to consider in the context of biosafety risk assessment and risk management.
Export Options
About this article
Cite this article as:
Lim Filip, Khalique Hena, Ventosa Maria and Baldo Aline, Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1, Current Gene Therapy 2013; 13(6) . https://dx.doi.org/10.2174/156652321306140103224550
DOI https://dx.doi.org/10.2174/156652321306140103224550 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Diagnostic and Therapeutic Applications of Exosome Nanovesicles in Lung Cancer:
State-of-The-Art
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Three Synthetic Membranes as Limiting Barrier for in vitro Drug Release Studies from Hydrogels Containing Polymeric Nanocapsules
Current Nanoscience Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Anti-MDR Effects of Quercetin and its Nanoemulsion in Multidrug-Resistant Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry In Vivo Applied Positively Charged FITC-Labeled Peptide Conjugates Show Artificial Relocation in Frozen Sections
Letters in Drug Design & Discovery Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals Comprehensive Analysis of Key Proteins Involved in Radioresistance of Prostate Cancer by Integrating Protein-protein Interaction Networks
Current Bioinformatics Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Uptake of [¹⁸F]tetrafluoroborate in MCF-7 Breast Cancer Cells is Induced after Stimulation of the Sodium Iodide Symporter
Current Cancer Drug Targets Chemical Modifications of Ketoprofen (NSAID) in Search of Better Lead Compounds: A Review of Literature From 2004-2016
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications
Current Neuropharmacology Synthesis and Characterization of Two New Thiophene Acetyl Salicylic Acid Esters and their ortho- and para-effect on Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry